FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
PO:07:108 | Achievement of Treatment Targets and Maintenance of Response with Upadacitinib in Patients with Moderate-to-Severe Rheumatoid Arthritis in a Real-world Setting: Final 2-year Outcomes from the UPHOLD Study Enrico Marchetta1, Andrew Östör2|8, Eugen Feist3, Prodromos Sidiropoulos4, Jérôme Avouac5, Martin Rebella6|7, Rajaie Namas9, Erin Mcdearmon Blondell10, Ivan Lagunes10, Tianming Gao10, Tim Shaw10, Suzan Attar11 | 1AbbVie Srl Roma, Italy; 2Monash University and Emeritus Research, Melbourne, Victoria, Melbourne, Australia; 3Helios Department of Rheumatology and Clinical Immunology, Vogelsang-Gommern, Vogelsang Gommern, Germany; 4Faculty of Medicine, University of Crete, Heraklion, Heraklion, Greece; 5Service de Rhumatologie, Hôpital Cochin, AP HP Centre Université Paris Cité, Parigi, France; 6Departamento de Medicina, Facultad de Medicina, Universidad de la República, Montevideo, Montevideo, Uruguay; 7Unidad de Enfermedades Autoinmunes Sistémicas, MUCAM, Montevideo, Montevideo, Uruguay; 8Australian National University, Camberra, Australia; 9Medical Subspecialties Institute, Division of Rheumatology, Cleveland Clinic Abu Dhabi, United Arab Emirates; 10AbbVie Inc., North Chicago, Illinois, United States of America Chicago, USA; 11King Abdulaziz University, Jeddah, Saudi Arabia
41 -
PO:16:227 | Anifrolumab for Systemic Lupus Erythematosus: Preliminary Safety and Efficacy Findings from the Italian Experience Paola Bizioli1|2, Chiara Orlandi1|2, Claudia Barison1|2, Cesare Tomasi3, Alessia Caproli1, Silvia Piantoni1|2, Simona Signorini4, Emirena Garrafa4, Cecilia Nalli1, Micol Frassi1, Ilaria Cavazzana1|2, Micaela Fredi1|2, Franco Franceschini1|2 | 1Rheumatology and Clinical Immunology Unit - ERN ReCONNET, ASST Spedali Civili of Brescia, Italy; 2Department of Clinical and Experimental Sciences, University of Brescia, Italy; 3Department of Clinical and Experimental Sciences, University of Brescia, Italy; 4Laboratory of Clinical Chemistry, Department of Molecular and Translational Medicine, University of Brescia, Italy
78 -
PO:36:246 | Early real-world outcomes with benralizumab in eosinophilic granulomatosis with polyangiitis: a monocentric retrospective Richard Borrelli1, Stefania Nicola1, Federica Corradi1, Iuliana Badiu1, Marzia Boem1, Valentina Marmora1, Simone Negrini1, Luisa Brussino1. | 1SCDU Immunologia e Allergologia, AO Mauriziano, Dipartimento di Scienze Mediche, Università degli Studi di Torino, Torino, Italy.
164 -
PO:14:193 | Dapirolizumab Pegol Demonstrated Significant Improvement in Systemic Lupus Erythematosus Disease Activity: Efficacy and Safety Results of a Phase 3 Trial Megan EB Clowse1, Marta Mosca2, David A Isenberg3, Joan T Merrill4, Thomas Dörner5, Michelle Petri6, Edward M Vital7|8, Eric F Morand9, Teri Jimenez10, Stephen Brookes11, Janine Gaiha-Rohrbach12, Christophe Martin13, Annette Nelde14, Christian Stach15 | 1Duke University - Division of Rheumatology and Immunology Durham, USA; 2University of Pisa - Rheumatology Unit, Department of Clinical and Experimental Medicine Pisa, Italy; 3University College London - Department of Ageing, Rheumatology and Regenerative Medicine, Division of Medicine London, United Kingdom; 4Oklahoma Medical Research Foundation Oklahoma City, USA; 5Charité Universitätsmedizin Berlin - Department of Medicine/Rheumatology and Clinical Immunology Berlin Germany; 6Johns Hopkins University School of Medicine Baltimore, USA; 7University of Leeds - Leeds Institute of Rheumatic and Musculoskeletal Medicine Leeds, United Kingdom; 8Leeds Teaching Hospitals NHS Trust - NIHR Leeds Biomedical Research Centre Leeds, United Kingdom; 9Monash University - Centre for Inflammatory Diseases Melbourne, Australia; 10UCB Raleigh, USA; 11Biogen Maidenhead, United Kingdom; 12Biogen Cambridge, USA; 13UCB Slough, United Kingdom; 14Biogen Baar, Switzerland; 15UCB Monheim am Rhein, Germany
76 -
PO:25:079 | Anifrolumab in refractory dermatomyositis: a case report Chiara Calabrese1, Corrado Campochiaro1|2, Giacomo De Luca 1|2, Veronica Batani1, Marco Matucci-Cerinic1|2, Lorenzo Dagna 1|2 | 1Dipartimento di Reumatologia e Scienze Mediche, ASST Centro Specialistico Ortopedico Traumatologico Gaetano Pini-CTO Milano; 2Università degli Studi di Milano, Dipartimento di Fisiopatologia Medico-Chirurgica e Trapianti, Milano, Italy
174 -
PO:06:089 | Heat-not-burn cigarettes induce protein post-translational modifications (PTM): possible role in the pathogenesis of rheumatoid arthritis Claudia Ciancarella1, Federica Maria Ucci1, Valeria Manganelli2, Elena Fasciolo2, Roberta Priori1, Fulvia Ceccarelli1, Manuel Sergi3, Camilla Montesano3, Francesco Bartolini3, Maurizio Sorice2, Cristiano Alessandri1, Fabrizio Conti1 | 1Rheumatology Unit, Department of Internal Medicine, Anesthesiology and Cardiovascular Sciences, La Sapienza, Roma, Italy; 2Department of Experimental Medicine, La Sapienza University of Rome, Italy; 3Department of Chemistry, La Sapienza University Of Rome, Italy
50 -
PO:17:255 | Efficacy and safety of voclosporin in the management of lupus nephritis: a case series Alessandra Oliva1, Elisabetta Chessa2, Marta Paola Pireddu1, Marianna Salis1, Giulia Rizzo1, Fabio Congiu1, Elena Ragusa1, Antonello Pani3|4, Alberto Cauli1|2, Nicola Lepori3|4, Matteo Piga1|2 | 1UOC Reumatologia, Dipartimento di Scienze Mediche e Salute Pubblica, Università degli Studi di Cagliari; 2UOC Reumatologia, AOU Cagliari; 3SC Nefrologia e Dialisi, Università degli Studi di Cagliari; 4SC Nefrologia e Dialisi, Azienda Ospedaliera Brotzu, Cagliari, Italy
179 -
PO:16:225 | Belimumab in refractory and/or non-criteria manifestations of antiphospholipid syndrome: ad interim analysis on Quality-of-Life changes from the BLAST trial Alessio Conti1, Lois Ira Capulong1, Irene Cecchi1, Elena Rubini1, Chiara Bova1, Massimo Radin1, Alice Barinotti1, Beatrice Ala1, Silvia Grazietta Foddai1, Daniela Rossi1, Roberta Fenoglio1, Savino Sciascia1 | 1Centro di Eccellenza Universitario per le Malattie Nefrologiche, Reumatologiche e Rare, S.G.Bosco -ASL Città di Torino, Italy
52 -
PO:07:099 | Survival on therapy of certolizumab pegol in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: 8-year data from an Italian multicenter register Maria Manara1, Gilberto Cincinelli1|2, Marco Fornaro3, Simone Perniola4, Elisa Gremese5, Chiara Bazzani6, Serena Bugatti7, Francesca Romana Spinelli8, Rosario Foti9, Marco Sebastiani10, Alberto Cauli11, Fabiola Atzeni12, Giovanni Lapadula13, Gianfranco Ferraccioli14, Fabrizio Conti8, Florenzo Iannone3, Roberto Caporali1|2 | 1Department of Rheumatology and Medical Sciences, ASST G. Pini-CTO Milano; 2Department of Clinical Sciences and Community Health, University of Milan; 3Department of Precision and Regenerative Medicine and Ionian Area, University of Bari; 4Clinical Immunology Division, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma; 5Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital, Rozzano (MI); 6Unit of Rheumatology and Clinical Immunology, ASST Spedali Civili Brescia; 7Department of Internal Medicine and Therapeutics, Università di Pavia; 8Rheumatology Unit, Dipartimento Scienze Cliniche Internistiche, Anestesiologiche e Cardiovascolari, Sapienza University, Roma; 9Rheumatology Unit, San Marco Hospital, Policlinico University of Catania; 10Rheumatology Unit, AUSL Piacenza, University of Parma; 11UOC di Reumatologia, Dipartimento di Scienze Mediche e Sanità Pubblica, Azienda Ospedaliero-Universitaria di Cagliari; 12Rheumatology Unit, Department of Experimental and Internal Medicine, University of Messina; 13Gruppo Italiano di Studio sulla Early Arthritis, GISEA, Bari; 14Department of Medicine, Università Cattolica del Sacro Cuore, Fondazione IRCCS Policlinico Gemelli, Roma, Italy
241 -
PO:16:232 | Belimumab step-down dose spacing in patients with systemic lupus erythematosus in persistent clinical remission: experience from a multicentric cohort Alice Bartoletti1, Laura Giudice1, Lorenza Maria Argolini1|2, Giuseppe Alvise Ramirez3, Luca Moroni3, Tommaso Schioppo4, Chiara Bellocchi5|6, Annalaura Fasiello6, Lorenzo Beretta6, Lorenzo Dagna3, Roberto Caporali1, Maria Gerosa1. | 1UO Clinica Reumatologica, ASST Gaetano Pini CTO, Milano, Italy; 2UOC Medicina fisica e riabilitazione specialistica, ASST Gaetano Pini CTO, Milano, Italy; 3Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Vita-Salute San Raffa Milano Italy; 4Medicina Generale II, Servizio di Reumatologia, Ospedale San Paolo, ASST Santi Paolo Carlo, Milano, Italy; 5Department of Clinical Sciences and Community Health, University of Milan, Dipartimeto di Eccellenza 2023-2027, Milano, Italy; 6Referral Centre for Systemic Autoimmune DIseases, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milano, Italy
208 -
PO:37:260 | Mepolizumab in the treatment of patients with eosinophilic granulomatosis with polyangiitis: real-life experience from a single-center cohort Eleonora Bruschi1, Fabrizio Angeli1, Alessandro Belotti Masserini1, Stefania Bertocchi1, Silvia Breda1, Elide Lupi1, Valeria Rossi1, Tania Ubiali1, Massimiliano Limonta1 | 1ASST Papa Giovanni XXIII Bergamo Italy
178 -
PO:06:086 | Updated Systematic Literature Review and meta-analysis to Inform the Italian Society of Rheumatology Recommendations on the Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease Angelo Fassio1, Marco Sebastiani9|10, Francesco Pollastri1, Chiara Crotti4, Nicola Ughi5, Enrico De Lorenzis6, Silvia Mancuso7, Massimo Radin8, Francesca Cozzini9, Greta Carrara11, Gianpiero Landolfi11, Roberto Rozza11, Andreina Manfredi2|3 | 1Rheumatology Unit, University of Verona, Verona, Italy; 2University of Modena and Reggio Emilia, Reggio Emilia, Italy; 3Rheumatology Unit, AUSL-IRCCS, Reggio Emilia, Italy; 4Bone Disease Unit, Department of Rheumatology and Medical Science, ASST-G.Pini-CTO, Milan, Italy; 5Division of Rheumatology, Multispecialist Medical Department, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy; 6Department of Aging Diseases, Orthopedic and Rheumatology, Rheumatology Division, P. Gemelli, Roma, Italy; 7Rheumatology Unit, Department of Clinical, Internal, Anaesthesiologic and Cardiovascular, Sciences, Sapienza, Roma, Italy; 8CMID, San Giovanni Bosco Hub Hospital ASL Città di Torino and Department of Clinical and Biological Sciences, Turin, Italy; 9Department of Medicine and Surgery, University of Parma, Parma, Italy; 10Rheumatology Unit, AUSL Piacenza, Piacenza, Italy; 11Unità Epidemiologica, SIR, Società Italiana di Reumatologia, Milano, Italy
43 -
PO:02:023 | Monocentric analysis of systemic glucocorticoids in PsA: the art of balancing prescriptive appropriateness and risk factor management Chiara Crotti1 2, Gilberto Cincinelli1, Giorgia Trignani13, Luca Ingrao13, Miriam Perino13, Roberto Caporali13 | 1Dipartimento di Reumatologia e Scienze Mediche - UOC Clinica Reumatologica, ASST Pini-CTO, Milano; 2Dipartimento di Reumatologia e Scienze Mediche - UOC Osteoporosi e Malattie Metaboliche dell Osso - ASST Pini-CTO, Milano; 3Dipartimento di Scienze Cliniche e di Comunità - Università degli Studi di Milano, Italy
204 -
PO:26:087 | Rituximab versus glucocorticoids for IgG4-related disease: a European retrospective multi-center study of 167 patients Marco Lanzillotta1, Jens Vikse2, Elisabetta Goni3, Jasmin Mahajne1, Veronica Batani1, Lorenzo Dagna1, Emanuel Della-Torre1 | 1Unit of Immunology, Rheumatology, Allergy, and Rare Disease, IRCCS Ospedale san Raffaele Milano, Italy; 2Department of Rheumatology, Stavanger University Hospital, Stavanger, Norway; 3Department of Medicine II, University Hospital, Ludwig Maximilian University Munich, Munich Germany
113 -
PO:02:022 | Bimekizumab Maintained Stringent Clinical Responses over 2 Years in Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies Fabian Proft1, Désirée Van Der Heijde2, Sergio Schwartzman3|4|5, Joerg Ermann6, Alexander Marten7, Ute Massow7, George Stojan8, Vanessa Taieb9, Diana Voiniciuc10, Astrid Van Tubergen11, Victoria Navarro-Compán12, Simone Angioni13, Xenofon Baraliakos14 | 1Charité-Universitätsmedizin Berlin; Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; 2Department of Rheumatology, Leiden University Medical Center Leiden, The Netherlands; 3Weill Cornell Medical Center New York, USA; 4New York Presbyterian Hospital New York, USA; 5Hospital for Special Surgery New York, USA; 6Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital and Harvard Medical School Boston, USA; 7UCB Monheim am Rhein Germany; 8UCB Atlanta, USA; 9UCB Colombes, France; 10UCB Slough, United Kingdom; 11Department of Medicine, Division of Rheumatology, Maastricht University Medical Center Maastricht, The Netherlands; 12Department of Rheumatology, La Paz University Hospital, IdiPaz Madrid, Spain; 13UCB Milan, Italy; 14Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Germany
41 -
PO:05:074 | A clinical case of a patient affected by long-standing psoriatic arthritis and multiple comorbidities treated with an anti-IL-23 therapy Maria Letizia Currò1, Angelo Tropea1, Alessandra Burgio1, Francesca Cracò1, Antonio Pezzano1, Federica Rapisarda1, Antonino Palumbo1, Valeria D'Amico1, Fabiola Atzeni1 | 1Clinica Reumatologica di Udine, Dipartimento di Medicina, ASUFC, Udine, Italy
166 -
PO:18:268 | Voclosporin as a Steroid-Sparing Agent in Lupus Nephritis Complicated by Central Serous Chorioretinopathy: A Case Report Irene Genovali1|2, Sebastiano Lorusso2, Damiano Currado1|2, Letizia Pia Di Corcia1, Ludovica Lamberti1, Annalisa Marino2, Antonio Orlando1, Maria Quadrini1, Marta Vadacca2, Marta Vomero1, Luca Navarini1|2, Roberto Giacomelli1|2 | 1Rheumatology and Clinical Immunology, Department of Medicine, University of Rome Campus Biomedico, School of Medicine Rome, Italy; 2Clinical and Research Section of Rheumatology and Clinical Immunology Fondazione Policlinico Campus Biomedico Rome, Italy
83 -
PO:29:138 | Cetylated fatty acids and fibromyalgia: efficacy and tolerability in a prospective study Anna Capogna1, Marco Bardelli1, Luca Cantarini1, Bruno Frediani1 | 1UOC Reumatologia, Dipartimento di Scienze mediche, chirurgiche e neuroscienze, Università degli Studi di Siena, Italy
175 -
PO:03:033 | Low Uveitis Rates in Patients with Axial Spondyloarthritis or Psoriatic Arthritis Treated with Bimekizumab: Long-Term Results from Phase 2b/3 Trials Irene E Van Der Horst-Bruinsma1, Matthew A Brown2, Floris A Van Gaalen3, Nigil Haroon4, Lianne S Gensler5, Alexander Marten6, Myriam Manente7, George Stojan8, Thomas Vaux9, Katy White9, Atul Deodhar10, Nicola Boffini11, Martin Rudwaleit12 | 1Department of Rheumatology, Radboud University Medical Centre Nijmegen, The Netherlands; 2Genomics England London, United Kingdom; 3Department of Rheumatology, Leiden University Medical Center Leiden, The Netherlands; 4Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto Toronto, Canada; 5Department of Medicine/Rheumatology, University of California San Francisco, USA; 6UCB Monheim am Rhein Germany; 7UCB Braine-lAlleud, Belgium; 8UCB Atlanta, USA; 9UCB Slough, United Kingdom; 10Division of Arthritis and Rheumatic Diseases, Oregon Health and Science University Portland, USA; 11IRCCS Ospedale San Raffaele Milan, Italy; 12Klinikum Bielefeld, University of Bielefeld, Bielefeld, Germany
34 -
PO:01:006 | Increased risk of cancer recurrence or mortality associated with DMARDs? Laura Scagnellato1, Giacomo Cozzi1, Mariagrazia Lorenzin1, Mariangela Salvato1, Alessandro Giollo1, Bernd Raffeiner1, Antonia Calligaro1, Teresa Del Ross1, Sara Bindoli1, Margherita Zen1, Paolo Sfriso1, Andrea Doria1, Roberta Ramonda1. | 1UOC Reumatologia, Dipartimento di Medicina dei Sistemi DIMED, Ospedale Università di Padova, Padova, Italy.
202 -
PO:02:018 | After-SECs: clinical predictors of secukinumab retention in psoriatic arthritis patients with inadequate response to anti-tumor necrosis factor therapy Francesco Cristiano1, Davide Gaspare Patti1, Valentina Boni1, Stefano Di Murro1, Cesare Gavotti1, Roberta Masnata1, Giulia Calabrese2, Gerlando Natalello2, Giusy Peluso2, Augusta Ortolan1|2, Enrico De Lorenzis1|2, Maria Antonietta D'Agostino1|2. | 1Università Cattolica del Sacro Cuore, Roma, Italy; 2Divisione di Reumatologia ed Immunologia clinica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy.
183 -
PO:35:223 | Biologic therapy for sustained remission in eosinophilic myocarditis: real-world evidence from a tertiary center experience Federica Davanzo1, Caterina Menghi2, Andrea Silvio Giordani2, Anna Baritussio2, Federico Scognamiglio2, Cristina Vicenzetto2, Luca Iorio1, Renzo Marcolongo2, Cristina Basso3, Andrea Doria1, Roberto Padoan1, Alida Linda Patr Caforio2 | 1Rheumatology Unit, Department of Medicine, University of Padua Padova, Italy; 2Cardiology Unit, Department of Cardiac, Vascular, Thoracic Sciences and Public Health, University of Padua Padova, Italy; 3Cardiovascular Pathology, Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padua Padova, Italy
53 -
PO:17:248 | Prevention of human papillomavirus infection in women with systemic lupus erythematosus: a single-center cross-sectional study Clizia Gagliardi1, Maria Chiara Gerardi1, Bianca Lucia Palermo1, Giulia Carrea1, Maria Di Cicco1, Elena Manna1, Giulia Segatto1, Antonella Adinolfi1, Laura Belloli1, Cinzia Casu1, Silvia Cavalli1, Davide Antonio Filippini1, Matteo Longhi1, Gabriella Maioli1, Martina Schettino1, Nicola Ughi1, Elisa Verduci1, Arianna Bertolucci1, Lara Buffa1, Giulia Buonsante1, Claudia Cordini1, Eleonora Giacobbe1, Francesco Molica Colella1, Oscar Epis1 | 1ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy
203 -
PO:01:011 | Achievement of Remission Defined by Absence of Objective Signs of Inflammation Versus ASDAS ID in Patients with Active Axial Spondyloarthritis Treated with Bimekizumab: 52-Week Results from Two Phase 3 Studies Lianne S Gensler1, Helena Marzo-Ortega2, Vanessa Taieb3, Diana Voiniciuc4, Alexander Marten5, George Stojan6, Mindy Kim6, Paolo Marsico7, Martin Rudwaleit8 | 1Department of Medicine/Rheumatology, University of California San Francisco, USA; 2NIHR Leeds Biomedical Research Centre, University of Leeds Leeds, United Kingdom; 3UCB Colombes, France; 4UCB Slough, United Kingdom; 5UCB Monheim am Rhein Germany; 6UCB Atlanta, USA; 7UCB Milan, Italy; 8University of Bielefeld, Klinikum Bielefeld Bielefeld Germany
42
